BASF Home
Global
Excipients for Drug Formulation
BASF Home
Global
Excipients for Drug Formulation
TOP
Global
Excipients for Drug Formulation

Solutions for your softgel
solubilization challenge

Solubilization Platform

Global
Excipients for Drug Formulation

Crystallization Inhibitors

BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body.

Crystallization inhibition is an important factor to maintain drug solubility and bioavailability out of solid and liquid dosage forms in particular. Before it can be adsorbed, recrystallization can happen at any point in time after formulation, during storage or administration, causing bioavailability to plummet and a consequent loss of medication efficacy. BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body, i.e. our low molecular weight povidones Kollidon® 12 PF and Kollidon® 17 PF or our Kollicoat® MAE 100-55.

Benefits

  • Product range of well established crystallization inhibitors
  • Extensive expertise in overcoming solubilization challenges
  • Trusted functional performance

Discover more about our crystallization inhibition solutions for softgel formulations

Portfolio Overview

Focusing on your needs with platform solutions

Download Center

Looking for application guides, technical and scientific posters, brochures or technical information? Visit our Download Center.

Discover our range of crystallization inhibitors for softgels

Kollidon® 12 PF

Low-molecular grade Kollidon®, intended for use as solubilizing agent, dispersant and crystallization inhibitor particularly for injectables. In addition applicable as pore former in solid dosage forms and viscosity enhancer in parenterals.

Kollidon® 17 PF

Low-molecular grade Kollidon®, intended for use as solubilizing agent, dispersant and crystallization inhibitor, particularly for injectables. In addition applicable as pore former in solid dosage forms and viscosity enhancer in parenterals.

Kollidon® 30

Our medium-molecular povidone is used in endless ways in pharmaceutical formulations - as binder, pore former, stabilizer, thickener, as solubilizing agent, crystallization inhibitor and many more. And with our trusted quality, it will always serve exactly what you intended it for.

Kollidon® 90 F

A highly effective binder, for use as a stabilizer in oral and topical suspensions, as a thickener, and as a hydrophilizing agent or pore-forming agent in medical plastics.

Kollidon® VA64

Kollidon® VA64 is used in granulation and as a dry binder in tablets, capsules and granules, as a film-forming agent in tablet coatings and subcoatings, and as a film-forming agent in topical sprays. Soluble copovidone widely used for instant release formulation and is suitable in hot-melt extrusion processes.

Related Solutions

Crystallization Inhibition

Crystallization inhibition is an important factor to maintain drug solubility and bioavailability out of solid and liquid dosage forms in particular. BASF offers a range of well established crystallization inhibitors that ensure that your drug will not get lost on its way to the point of action in the body.

Softgels Platform

Functional solutions for all soft gel parts – fill, shell and coating.

Solubilization Platform

Effective solubilization in solid & liquid dosage forms.